These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17785672)

  • 1. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model.
    Kasteleijn-Nolst Trenité DG; Genton P; Parain D; Masnou P; Steinhoff BJ; Jacobs T; Pigeolet E; Stockis A; Hirsch E
    Neurology; 2007 Sep; 69(10):1027-34. PubMed ID: 17785672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: a placebo-controlled, exploratory study.
    Di Prospero NA; Gambale JJ; Pandina G; Ford L; Girgis S; Moyer JA; Xi L; Nye JS; Kasteleijn-Nolst Trenité D
    Epilepsy Res; 2014 May; 108(4):709-16. PubMed ID: 24560845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship.
    Kasteleijn-Nolst Trenité D; Brandt C; Mayer T; Rosenow F; Schmidt B; Steinhoff BJ; Gardin A; Imbert G; Johns D; Sagkriotis A; Kucher K
    Epilepsia; 2015 Jun; 56(6):924-32. PubMed ID: 25963722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study.
    Trenité DG; French JA; Hirsch E; Macher JP; Meyer BU; Grosse PA; Abou-Khalil BW; Rosenfeld WE; van Gerven J; Novak GP; Parmeggiani L; Schmidt B; Gibson D; Guerrini R
    Epilepsy Res; 2007 May; 74(2-3):193-200. PubMed ID: 17448639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089).
    Kasteleijn-Nolst Trenite DGA; DiVentura BD; Pollard JR; Krauss GL; Mizne S; French JA
    Neurology; 2019 Aug; 93(6):e559-e567. PubMed ID: 31292226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brivaracetam: new compound approved for the treatment of epilepsy.
    Zaccara G
    Drugs Today (Barc); 2016 Apr; 52(4):219-27. PubMed ID: 27252986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator.
    Gurrell R; Gorman D; Whitlock M; Ogden A; Reynolds DS; DiVentura B; Abou-Khalil B; Gelfand M; Pollard J; Hogan RE; Krauss G; Sperling M; Vazquez B; Wechsler RT; Friedman D; Butt RP; French J
    Neurology; 2019 Apr; 92(15):e1786-e1795. PubMed ID: 30877186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kv7 potassium channel activation with ICA-105665 reduces photoparoxysmal EEG responses in patients with epilepsy.
    Kasteleijn-Nolst Trenité DG; Biton V; French JA; Abou-Khalil B; Rosenfeld WE; Diventura B; Moore EL; Hetherington SV; Rigdon GC
    Epilepsia; 2013 Aug; 54(8):1437-43. PubMed ID: 23692516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects.
    Sargentini-Maier ML; Espié P; Coquette A; Stockis A
    Drug Metab Dispos; 2008 Jan; 36(1):36-45. PubMed ID: 17908923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.
    Strzelczyk A; Klein KM; Willems LM; Rosenow F; Bauer S
    Expert Rev Clin Pharmacol; 2016; 9(5):637-45. PubMed ID: 26891946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single dose efficacy evaluation of two partial benzodiazepine receptor agonists in photosensitive epilepsy patients: A placebo-controlled pilot study.
    Kasteleijn-Nolst Trenité DG; Groenwold RH; Schmidt B; Löscher W
    Epilepsy Res; 2016 May; 122():30-6. PubMed ID: 26921854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brivaracetam prevents astroglial l-glutamate release associated with hemichannel through modulation of synaptic vesicle protein.
    Okada M; Fukuyama K; Shiroyama T; Ueda Y
    Biomed Pharmacother; 2021 Jun; 138():111462. PubMed ID: 33706129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males.
    Sargentini-Maier ML; Rolan P; Connell J; Tytgat D; Jacobs T; Pigeolet E; Riethuisen JM; Stockis A
    Br J Clin Pharmacol; 2007 Jun; 63(6):680-8. PubMed ID: 17223857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brivaracetam disposition in mild to severe hepatic impairment.
    Stockis A; Sargentini-Maier ML; Horsmans Y
    J Clin Pharmacol; 2013 Jun; 53(6):633-41. PubMed ID: 23649964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivaracetam for the treatment of epilepsy.
    Klein P; Tyrlikova I; Brazdil M; Rektor I
    Expert Opin Pharmacother; 2016; 17(2):283-95. PubMed ID: 26760311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Brivaracetam for add-on treatment in focal epilepsy].
    Strzelczyk A; Steinig I; Klein KM; Willems LM; Knake S; Rosenow F; Bauer S
    Nervenarzt; 2016 Oct; 87(10):1086-1093. PubMed ID: 27389600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants.
    French JA; Wechsler R; Gelfand MA; Pollard JR; Vazquez B; Friedman D; Gong LH; Kamemoto E; Isojarvi J; Cassella JV
    Epilepsia; 2019 Aug; 60(8):1602-1609. PubMed ID: 31268555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.